Evidence map›Paper›PMID 29988514›Full record

ArticleTranslational neurodegeneration2018

Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.

Zhenxin Zhang, Ming Shao, Shengdi Chen, Chunfeng Liu, Rong Peng, Yansheng Li, Jian Wang, Suiqiang Zhu, Qiumin Qu, Xiaoying Zhang and 8 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational neurodegeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479530 (Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China), which is not on this map. Cited by 22 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 6 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01479530 phase3completednot on this map

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

TypeinterventionalSponsorH. Lundbeck A/SRan2011 to 2013Enrolled321ConditionsParkinson's DiseaseArmsPlacebo, Azilect®
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interventions for preventing falls in Parkinson's disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Happiness: A Novel Outcome in Parkinson Studies?Journal of Parkinson's disease · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 17 institutions in 1 country.

Zhenxin Zhang1Department of Neurology, Peking Union Medical College Hospital, 53 Dongdan N St, Dongcheng, Beijing, China.ORCID 0000-0003-1659-8951
Ming Shao2Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shengdi Chen3Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chunfeng Liu4Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Rong Peng5Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Yansheng Li6Department of Neurology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jian Wang7Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Suiqiang Zhu8Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qiumin Qu9Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaoying Zhang10Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Haibo Chen11Department of Neurology, Beijing Hospital, Beijing, China.
Xiangru Sun12Department of Neurology, Peking University First Hospital, Beijing, China.
Yanping Wang13Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shenggang Sun14Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Baorong Zhang15Department of Neurology, The Second Affiliated hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou China.
Jimei Li16Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaoping Pan17Department of Neurology, Guangzhou First People's Hospital, Guangzhou, China.
Gang Zhao18Department of Neurology, Xijing Hospital, The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, China.
Capital Medical University · CNBeijing United Family Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Guangzhou Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFudan University · CNGuangzhou First People's Hospital · CNPeking University · CNRenji Hospital · CNRuijin Hospital · CNSecond Affiliated Hospital of Guangzhou Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNSichuan University · CNSoochow University · CNTongji Hospital · CNUnion Hospital · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of adjunct rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations is supported by findings from large-scale clinical studies. This study is to investigate the efficacy and safety of adjunct rasagiline in Chinese patients with Parkinson's disease, as a product registration study.

methodsThis 16-week, randomized, double-blind, parallel-group, multicenter, placebo-controlled study of rasagiline 1 mg/day included levodopa-treated patients with Parkinson's disease and motor fluctuations. The primary efficacy endpoint was mean change from baseline in total daily OFF time over 16 weeks. Secondary endpoints were Clinical Global Impressions - Improvement (CGI-I), and change in Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (ADL) and Motor scores. Patient well-being (EQ-5D), and the frequency of adverse events were also assessed.

resultsIn total, 324 levodopa-treated patients were randomized to rasagiline 1 mg/day (

conclusionsIn levodopa-treated Chinese patients with Parkinson's disease and motor fluctuations, adjunct rasagiline 1 mg/day statistically significantly reduced OFF time, and improved daily function and overall well-being, versus placebo. Consistent with findings in other countries, adjunct rasagiline was proven efficacious and well tolerated in Chinese patients. TRIAL REGISTRATION NUMBER: NCT01479530. Registered 22 November 2011.

Indexed as

AdjunctChinaMotor fluctuationsOFF timeParkinson’s diseaseQuality of lifeRasagiline

Identifiers

PMID29988514
PMCPMC6026338
OpenAlexW2811061566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.